Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification Assay.

Saved in:
Bibliographic Details
Title: Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification Assay.
Authors: Brooker SM; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Pasquini J; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK.; Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Choi SH; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA., Lafontant DE; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA., Fereshtehnejad SM; Division of Neurology, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada.; Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, UHN, Toronto, Ontario, Canada.; Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institute, Stockholm, Sweden., Zeighami Y; Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada.; Integrated Program in Neuroscience, McGill University, Montreal, Quebec, Canada., Grillo P; The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, Department of Neurology, NYU Langone Health, New York, New York, USA.; Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.; IRCCS Mondino Foundation, Pavia, Italy., Riboldi GM; Department of Neurology, NYU Grossman School of Medicine, New York, New York, USA., Azizi H; Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada.; Integrated Program in Neuroscience, McGill University, Montreal, Quebec, Canada.; Neuro (Montreal Neurological Institute-Hospital), McGill University, Montreal, Quebec, Canada., Moqadam R; Douglas Mental Health University Institute, Department of Psychiatry, McGill University, Montreal, Quebec, Canada., Kang UJ; The Marlene and Paolo Fresco Institute for Parkinson's and Movement Disorders, Department of Neurology, NYU Langone Health, New York, New York, USA.; Department of Neurology, NYU Grossman School of Medicine, New York, New York, USA.; Department of Neuroscience, NYU Grossman School of Medicine, New York, New York, USA.; Parekh Center for interdisciplinary Neurology, NYU Langone Health, New York, New York, USA., Nudelman KNH; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA., Siderowf A; Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA., Tanner CM; Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA., Tropea TF; Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA., Foroud T; Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA., Chahine LM; Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Mollenhauer B; Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.; Paracelsus-Elena-Klinik Kassel, Kassel, Germany., Merchant KM; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Galasko D; Department of Neurosciences, University of California San Diego, La Jolla, California, USA., Coffey CS; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA., Dobkin RD; Department of Psychiatry, Rutgers University, Robert Wood Johnson Medical School, Piscataway, New Jersey, USA., Brown EG; Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA., Alcalay RN; Division of Movement Disorders, Department of Neurology, Tel Aviv Soursaky Medical Center, Tel Aviv, Israel.; Columbia University Irving Medical Center, New York, New York, USA., Weintraub D; Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.; Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.; Philadelphia Department of Veterans Affairs, Parkinson's Disease Research, Education and Clinical Center, Philadelphia, Pennsylvania, USA., Marek K; Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA., Simuni T; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Gonzalez-Latapi P; Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Pavese N; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne, UK., Poston KL; Department of Neurology and Neurological Sciences, Stanford University, Stanford, California, USA.; Department of Neurosurgery, Stanford University, Stanford, California, USA.; Wu Tsai Neuroscience Institute, Stanford University, Stanford, California, USA.; Knight Initiative for Brain Resilience, Stanford University, Stanford, California, USA.
Corporate Authors: Parkinson's Progression Markers Initiative
Source: Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2026 May; Vol. 41 (5), pp. 1114-1127. Date of Electronic Publication: 2026 Jan 28.
Publication Type: Journal Article
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8610688 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8257 (Electronic) Linking ISSN: 08853185 NLM ISO Abbreviation: Mov Disord Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1531-8257
DOI:10.1002/mds.70197